Successful Local Administration of an IL-17 Inhibitor in ACH Treatment
Overview
This report details a successful case of local IL-17 inhibitor injections in a 13-year-old girl with refractory acrodermatitis continua of Hallopeau (ACH), avoiding systemic immune drift. The treatment led to significant improvement in skin lesions and quality of life without the adverse effects typically associated with systemic therapies.
Background
Acrodermatitis continua of Hallopeau (ACH) is a chronic and challenging skin disorder characterized by pustular lesions primarily affecting the distal extremities. Traditional treatments often yield poor results and can lead to immune imbalances. The use of biologic agents targeting the IL-17 pathway has shown promise, but systemic administration may provoke adverse immune responses, necessitating alternative local treatment strategies.
Data Highlights
Assessment
Baseline
Week 16
PPPASI
14.4
0
DLQI
24
0
NAPSI
160
0
Key Findings
Local injections of Xeligekimab effectively treated refractory ACH lesions.
The patient experienced significant improvement in PPPASI, DLQI, and NAPSI scores.
Systemic immune drift was avoided through localized treatment.
Previous systemic therapies, including acitretin and upadacitinib, were ineffective.
Local administration of IL-17 inhibitors may represent a novel approach for managing ACH.
Clinical Implications
The findings suggest that local administration of IL-17 inhibitors can be a viable treatment option for patients with refractory ACH, potentially minimizing systemic side effects. Clinicians should consider this approach for patients who do not respond to conventional therapies.
Conclusion
Local injection of IL-17 inhibitors may provide an effective treatment alternative for refractory ACH, warranting further investigation to validate these findings in larger cohorts.
